Orgenesis Inc (ORGS)
OTHER OTC:ORGS
Want to see ORGS full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/A
Date:―
No summary available
Positive Factors
Business Model Innovation
The POCare platform represents a strategic shift towards decentralized therapy production, potentially reducing costs and improving patient access, which can enhance long-term market positioning and competitiveness.
Negative Factors
Financial Instability
Negative equity and financial instability indicate a leveraged position, posing risks to financial health and necessitating urgent strategic realignment or external support.
Read all positive and negative factors
Positive Factors
Negative Factors
Business Model Innovation
The POCare platform represents a strategic shift towards decentralized therapy production, potentially reducing costs and improving patient access, which can enhance long-term market positioning and competitiveness.
Read all positive factors
Orgenesis (ORGS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.78M
Dividend YieldN/A
Average Volume (3M)979.00
Price to Earnings (P/E)―
Beta (1Y)10.73
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees146
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,799,538
10 Day Avg. Volume591
30 Day Avg. Volume979
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-6.91
Price to Sales (P/S)273.66
P/FCF Ratio-8.57
Enterprise Value/Market Cap4.30
Enterprise Value/Revenue-1.93
Enterprise Value/Gross Profit-1.35
Enterprise Value/Ebitda-0.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Orgenesis Business Overview & Revenue Model
Company Description
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated P...
How the Company Makes Money
Orgenesis makes money primarily through its Point-of-Care (POCare) platform, which enables the localized production of cell and gene therapies. The company partners with healthcare providers, research institutions, and biotech companies to develop...
Orgenesis Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Mar 2024 | Dec 2022 | Dec 2021 | Dec 2020 | Nov 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -12.87M | 530.00K | 36.02M | 35.50M | 7.65M | 33.26M |
| Gross Profit | -18.37M | -5.72M | 15.59M | 7.34M | -23.45M | 15.14M |
| EBITDA | -68.24M | -60.72M | -8.16M | -15.72M | -94.21M | -18.91M |
| Net Income | -43.94M | -55.36M | -14.89M | -18.06M | -95.81M | -26.04M |
Balance Sheet | ||||||
| Total Assets | 29.69M | 14.55M | 90.93M | 59.84M | 77.68M | 92.50M |
| Cash, Cash Equivalents and Short-Term Investments | 204.00K | 837.00K | 5.31M | 5.47M | 44.92M | 11.39M |
| Total Debt | 17.30M | 22.62M | 20.27M | 11.84M | 12.91M | 24.78M |
| Total Liabilities | 53.62M | 35.53M | 31.65M | 21.21M | 24.96M | 86.42M |
| Stockholders Equity | -23.90M | -20.98M | 27.56M | 38.49M | 52.58M | 5.48M |
Cash Flow | ||||||
| Free Cash Flow | -15.80M | -16.93M | -37.34M | -34.73M | -79.57M | -25.35M |
| Operating Cash Flow | -15.48M | -14.84M | -24.92M | -26.87M | -78.05M | -13.22M |
| Investing Cash Flow | 11.00K | -3.71M | -14.13M | -12.38M | 105.61M | -13.78M |
| Financing Cash Flow | 15.79M | 13.62M | 39.58M | -106.00K | 5.88M | 24.10M |
Orgenesis Technical Analysis
Neutral
0.16
Price Trends
0.42
Positive
0.40
Positive
0.41
Positive
Market Momentum
0.03
Negative
51.17
Neutral
84.65
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORGS, the sentiment is Neutral. The current price of 0.16 is below the 20-day moving average (MA) of 0.45, below the 50-day MA of 0.42, and below the 200-day MA of 0.41, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 51.17 is Neutral, neither overbought nor oversold. The STOCH value of 84.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ORGS.
Orgenesis Risk Analysis
Orgenesis disclosed 47 risk factors in its most recent earnings report. Orgenesis reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Orgenesis Peers Comparison
UnderperformOutperform
Sector (51)
ORGS
Orgenesis
0.49
-1.26
-72.00%
SCNI
Scinai Immunotherapeutics
0.44
-2.81
-86.49%
GTBP
GT Biopharma
0.48
-2.22
-82.34%
ADTX
Aditxt
0.08
-35,147.44
-100.00%
PBM
Psyence Biomedical
3.69
-28.19
-88.42%
CDT
CDT Equity
0.85
-539.15
-99.84%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―